Samjin Pharm - Asset Resilience Ratio
Samjin Pharm (005500) has an Asset Resilience Ratio of 0.25% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Samjin Pharm's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Samjin Pharm's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 005500 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Samjin Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Samjin Pharm's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.11 Billion | 0.25% |
| Total Liquid Assets | ₩1.11 Billion | 0.25% |
Asset Resilience Insights
- Limited Liquidity: Samjin Pharm maintains only 0.25% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Samjin Pharm Industry Peers by Asset Resilience Ratio
Compare Samjin Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM |
Drug Manufacturers - Specialty & Generic | 2.79% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 2.51% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664 |
Drug Manufacturers - Specialty & Generic | 0.97% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Samjin Pharm (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Samjin Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.07% | ₩287.63 Million ≈ $194.92K |
₩425.17 Billion ≈ $288.13 Million |
-0.31pp |
| 2023-12-31 | 0.38% | ₩1.60 Billion ≈ $1.09 Million |
₩419.90 Billion ≈ $284.56 Million |
-0.19pp |
| 2022-12-31 | 0.57% | ₩2.32 Billion ≈ $1.57 Million |
₩406.56 Billion ≈ $275.52 Million |
-0.56pp |
| 2021-12-31 | 1.13% | ₩3.77 Billion ≈ $2.55 Million |
₩332.50 Billion ≈ $225.33 Million |
-0.94pp |
| 2020-12-31 | 2.07% | ₩5.58 Billion ≈ $3.78 Million |
₩269.03 Billion ≈ $182.32 Million |
-0.13pp |
| 2019-12-31 | 2.21% | ₩5.39 Billion ≈ $3.65 Million |
₩244.15 Billion ≈ $165.46 Million |
+0.35pp |
| 2018-12-31 | 1.86% | ₩4.66 Billion ≈ $3.15 Million |
₩250.27 Billion ≈ $169.61 Million |
-0.83pp |
| 2017-12-31 | 2.69% | ₩6.50 Billion ≈ $4.40 Million |
₩241.85 Billion ≈ $163.90 Million |
-0.44pp |
| 2016-12-31 | 3.13% | ₩7.12 Billion ≈ $4.83 Million |
₩227.57 Billion ≈ $154.22 Million |
+1.37pp |
| 2015-12-31 | 1.76% | ₩3.89 Billion ≈ $2.64 Million |
₩220.74 Billion ≈ $149.59 Million |
+0.09pp |
| 2014-12-31 | 1.67% | ₩3.50 Billion ≈ $2.37 Million |
₩209.31 Billion ≈ $141.84 Million |
-0.96pp |
| 2013-12-31 | 2.63% | ₩5.37 Billion ≈ $3.64 Million |
₩203.95 Billion ≈ $138.21 Million |
-- |
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more